{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:02:18Z","timestamp":1784599338962,"version":"3.55.0"},"reference-count":41,"publisher":"ARAN Ediciones","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.hipert.2019.05.005","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T16:08:54Z","timestamp":1562429334000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nuevas perspectivas en el tratamiento de la hipercolesterolemia desde la disponibilidad de los inhibidores de la prote\u00edna PCSK9"],"prefix":"10.20960","volume":"36","author":[{"given":"X.","family":"Pint\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sarasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2019.05.005_bib0210","first-page":"939","volume":"69","author":"Piepoli","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"Suppl 2","key":"10.1016\/j.hipert.2019.05.005_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.hipert.2019.05.005_bib0220","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1.Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2019.05.005_bib0225","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2019.05.005_bib0230","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2019.05.005_bib0235","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hipert.2019.05.005_bib0240","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hipert.2019.05.005_bib0245","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.medcli.2011.07.023","article-title":"Inertia and treatment compliance in patients with type 2 diabetes in primary care","volume":"138","author":"L\u00f3pez-Simarro","year":"2012","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.hipert.2019.05.005_bib0250","first-page":"115","article-title":"[2016 ESC\/EAS guidelines for the management of dyslipidaemias]","volume":"70","author":"Catapano","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"10.1016\/j.hipert.2019.05.005_bib0255","doi-asserted-by":"crossref","first-page":"e22566","DOI":"10.1002\/jcla.22566","article-title":"Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia","volume":"7","author":"Cano-Corres","year":"2018","journal-title":"J Clin Lab Anal."},{"key":"10.1016\/j.hipert.2019.05.005_bib0260","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.hipert.2019.05.005_bib0265","first-page":"155","article-title":"Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society","volume":"25","author":"Pedro-Botet","year":"2013","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.hipert.2019.05.005_bib0270","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de posicionamiento terap\u00e9utico PT-evolocumab\/V1\/03032016 Informe de Posicionamiento Terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia. Fecha de publicaci\u00f3n: 3 de Mar de 2016."},{"key":"10.1016\/j.hipert.2019.05.005_bib0275","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de posicionamiento terap\u00e9utico PT-alirocumab\/V1\/22042016 Informe de Posicionamiento Terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia. Fecha de publicaci\u00f3n: 22 de Abr de 2016."},{"key":"10.1016\/j.hipert.2019.05.005_bib0280","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11886-019-1103-2","article-title":"The new face of hyperlipidemia and the role of PCSK9 inhibitors","volume":"21","author":"Nicholls","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.hipert.2019.05.005_bib0285","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/1060028018771670","article-title":"The role of PCSK9 inhibitors in the treatment of hypercholesterolemia","volume":"52","author":"Patel","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.hipert.2019.05.005_bib0290","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3909\/ricm0741","article-title":"Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: Focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies","volume":"15","author":"Verma","year":"2014","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.hipert.2019.05.005_bib0295","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2019.05.005_bib0300","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2019.05.005_bib0305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCRESAHA.118.314191","article-title":"Application of PCSK9 inhibitors in practice","volume":"124","author":"Kaufman","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.hipert.2019.05.005_bib0310","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisinkexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2019.05.005_bib0315","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosissup.2018.04.072","article-title":"Lp(a) and cardiovascular outcomes: An analysis from the ODYSSEY OUTCOMES Trial","volume":"32","author":"Bittner","year":"2018","journal-title":"Arterioscler Suppl"},{"key":"10.1016\/j.hipert.2019.05.005_bib0320","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a) PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2019.05.005_bib0325","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: A new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J Cardiol"},{"key":"10.1016\/j.hipert.2019.05.005_bib0330","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/jamacardio.2017.3944","article-title":"Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hipert.2019.05.005_bib0335","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2019.05.005_bib0340","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events: The ODYSSEY OUTCOMES trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2019.05.005_bib0345","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2019.05.005_bib0350","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2016.05.010","volume":"178","author":"Ridker","year":"2016","journal-title":"Am Heart J."},{"key":"10.1016\/j.hipert.2019.05.005_bib0355","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.hipert.2019.05.005_bib0360","first-page":"164","article-title":"[Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9]","volume":"28","author":"Masana","year":"2016","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.hipert.2019.05.005_bib0365","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.recesp.2016.05.013","article-title":"Challenges in oral lipid-lowering therapy: Position document of the Spanish Society of Cardiology","volume":"69","author":"Anguita S\u00e1nchez","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.hipert.2019.05.005_bib0370","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hipert.2019.05.005_bib0375","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.recesp.2018.02.013","article-title":"Cost-effectiveness and budget impact of treatment with evolocumab versus statins and ezetimibe for hypercholesterolemia in Spain","volume":"71","author":"Olry de Labry Lima","year":"2018","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.hipert.2019.05.005_bib0380","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/jamacardio.2017.3944","article-title":"Clinical efficacy and safety of evolocumab in high risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hipert.2019.05.005_bib0385","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: A prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hipert.2019.05.005_bib0390","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2019.05.005_bib0395","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.recesp.2018.11.017","article-title":"Estimated percentage of patients with stable coronary heart disease candidates for PCSK9 inhibitors","volume":"72","author":"Cordero","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"10.1016\/j.hipert.2019.05.005_bib0400","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.recesp.2017.11.006","article-title":"Number of patients eligible for PCSK9 inhibitors based on real-world data from 2.5 million patients","volume":"71","author":"Zamora","year":"2018","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.hipert.2019.05.005_bib0405","doi-asserted-by":"crossref","first-page":"e011246","DOI":"10.1161\/JAHA.118.011246","article-title":"PCSK9 inhibitor use in the real world: Data from the national patient-centered research network","volume":"8","author":"Chamberlain","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.hipert.2019.05.005_bib0410","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","author":"Grundy","year":"2018","journal-title":"Circulation."}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183719300480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183719300480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:12Z","timestamp":1784596512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183719300480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1889183719300480"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2019.05.005","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuevas perspectivas en el tratamiento de la hipercolesterolemia desde la disponibilidad de los inhibidores de la prote\u00edna PCSK9","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2019.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}